Shares of Myovant Sciences Ltd (NYSE:MYOV) have received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $26.75.
Several research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Myovant Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research cut shares of Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 17th.
In other Myovant Sciences news, Director Mark Altmeyer purchased 3,500 shares of the company’s stock in a transaction dated Saturday, November 17th. The shares were acquired at an average price of $13.38 per share, for a total transaction of $46,830.00. Following the purchase, the director now directly owns 3,500 shares of the company’s stock, valued at approximately $46,830. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 3.10% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in shares of Myovant Sciences during the 2nd quarter valued at $297,000. Matisse Capital purchased a new position in shares of Myovant Sciences during the 2nd quarter valued at $349,000. Swiss National Bank lifted its stake in shares of Myovant Sciences by 12.7% during the 1st quarter. Swiss National Bank now owns 28,300 shares of the company’s stock valued at $602,000 after buying an additional 3,200 shares in the last quarter. Platinum Investment Management Ltd. purchased a new position in shares of Myovant Sciences during the 1st quarter valued at $1,152,000. Finally, Millennium Management LLC lifted its stake in shares of Myovant Sciences by 54.3% during the 1st quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock valued at $2,273,000 after buying an additional 37,602 shares in the last quarter. Institutional investors own 21.03% of the company’s stock.
NYSE:MYOV traded down $0.06 during trading hours on Friday, reaching $23.41. The company had a trading volume of 5,066 shares, compared to its average volume of 52,058. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.73. Myovant Sciences has a 52 week low of $11.30 and a 52 week high of $25.54. The company has a market cap of $1.57 billion, a PE ratio of -9.87 and a beta of -1.96.
Myovant Sciences (NYSE:MYOV) last posted its earnings results on Tuesday, August 7th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.08). research analysts forecast that Myovant Sciences will post -3.9 earnings per share for the current year.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Featured Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.